RCS - Nuformix PLC - NXP002 data to be presented at 2022 ERS Congress

NuformixAnnouncement

05/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220705:nRSE1779Ra&default-theme=true

RNS Number : 1779R  Nuformix PLC  05 July 2022

Reach

 

5 July 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

NXP002 data to be presented at the 2022 European Respiratory Society Congress

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that both of the abstracts submitted for presentation at the European
Respiratory Society ("ERS") International Congress 2022 in Barcelona on
September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted
for presentation.  NXP002 is a potential novel inhaled treatment for
Idiopathic Pulmonary Fibrosis ("IPF").

 

Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We
believe NXP002 offers tremendous potential as a novel inhaled treatment for
IPF and potentially other fibrosing interstitial lung diseases ("ILDs").  The
Company is progressing a pre-clinical programme to demonstrate how its
proprietary new form of tranilast can down regulate fibrosis and inflammation
following inhalation, whilst avoiding severe side effects, which are key
issues in the treatment of IPF and other ILDs.  We are therefore delighted
that the abstracts describing our initial work have been accepted following
peer review.

 

"The ERS is a leading international respiratory congress.  It provides us the
opportunity to share these positive data with the scientific and clinical
communities and, very importantly, the congress is attended by all the major
respiratory-focused pharmaceutical companies.  Ultimately, we will be looking
to license NXP002 and the congress offers us an important opportunity to
present and introduce NXP002 to potential licensing partners."

 

Enquiries:

 

 Nuformix plc
 Dr Julian Gilbert, Non-executive Director         Via IFC Advisory

 Maddy Kennedy, Non-executive Director

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRARIMRTMTTMMMT